XKRX145020
Market cap2.22bUSD
Dec 24, Last price
279,500.00KRW
1D
0.00%
1Q
14.31%
Jan 2017
-12.96%
IPO
57.55%
Name
Hugel Inc
Chart & Performance
P/E
34.53
P/S
10.05
EPS
8,093.47
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
25.75%
Revenues
319.70b
+13.50%
Net income
93.08b
+62.35%
CFO
117.71b
+45.99%
Earnings
Feb 12, 2025
Profile
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 319,699,941 13.50% | 281,675,135 21.49% | 231,859,108 9.87% | ||
Cost of revenue | 152,399,854 | 136,780,617 | 100,609,040 | ||
Unusual Expense (Income) | |||||
NOPBT | 167,300,087 | 144,894,518 | 131,250,069 | ||
NOPBT Margin | 52.33% | 51.44% | 56.61% | ||
Operating Taxes | 35,609,451 | 9,178,330 | 28,273,334 | ||
Tax Rate | 21.28% | 6.33% | 21.54% | ||
NOPAT | 131,690,636 | 135,716,188 | 102,976,735 | ||
Net income | 93,076,069 62.35% | 57,331,826 -0.69% | 57,730,176 37.48% | ||
Dividends | (105,914) | ||||
Dividend yield | 0.01% | ||||
Proceeds from repurchase of equity | (121,682,383) | (44,514,708) | (34,631,497) | ||
BB yield | 6.94% | 2.73% | 1.82% | ||
| Debt | |||||
Debt current | 607,777 | 99,443,672 | 1,582,944 | ||
Long-term debt | 91,589,517 | 4,166,252 | 101,370,896 | ||
Deferred revenue | 261,847 | 958,132 | |||
Other long-term liabilities | 2,232,243 | 19,766,636 | 18,523,956 | ||
Net debt | (37,297,484) | (118,068,406) | (280,824,675) | ||
| Cash flow | |||||
Cash from operating activities | 117,705,306 | 80,626,442 | 85,940,035 | ||
CAPEX | (23,717,287) | (45,028,876) | (48,401,539) | ||
Cash from investing activities | 43,198,399 | (191,831,664) | 180,130,227 | ||
Cash from financing activities | (187,068,752) | (51,369,969) | (36,027,647) | ||
FCF | 72,745,011 | 109,489,933 | 102,405,615 | ||
| Balance | |||||
Cash | 481,932,611 | 531,360,147 | 556,404,143 | ||
Long term investments | (352,437,833) | (309,681,817) | (172,625,628) | ||
Excess cash | 113,509,781 | 207,594,574 | 372,185,559 | ||
Stockholders' equity | 627,801,189 | 962,774,712 | 899,678,796 | ||
Invested Capital | 758,923,206 | 679,239,816 | 507,106,951 | ||
ROIC | 18.31% | 22.88% | 15.71% | ||
ROCE | 19.18% | 15.32% | 13.94% | ||
| EV | |||||
Common stock shares outstanding | 11,731 | 12,088 | 12,394 | ||
Price | 149,400.00 10.75% | 134,900.00 -12.12% | 153,500.00 -18.26% | ||
Market cap | 1,752,655,025 7.48% | 1,630,626,818 -14.29% | 1,902,443,542 -18.13% | ||
EV | 1,747,725,251 | 1,902,162,141 | 2,007,668,383 | ||
EBITDA | 181,160,458 | 158,888,645 | 145,549,170 | ||
EV/EBITDA | 9.65 | 11.97 | 13.79 | ||
Interest | 3,111,578 | 3,721,006 | |||
Interest/NOPBT | 2.15% | 2.84% | |||